Image For Activity Cover
Regulatory Issues and Medications for Opioid Use Disorder (MOUD)
SUD 101 Core Curriculum Overview

Curriculum overview:  While healthcare professionals are often on the front lines of treating substance use disorders, most have limited (if any) training in this area. The SUD 101 Core Curriculum was created to provide a foundation of the current research, resources, and support needed to increase healthcare professionals’ competence and confidence in the care of their patients across the continuum of care. This activity, Regulatory Issues and Medications for Opioid Use Disorder (MOUD), is part of the 23-module curriculum. Please see below for a summary of module 13 out of 23:
Module 13 Overview
Title: Regulatory Issues and Medications for Opioid Use Disorder (MOUD) 

Presenter(s):
Brian Hurley, M.D.,
County of Los Angeles, Department of Public Health, University of California, Los Angeles

Module Description: At the conclusion of this activity participants should be able to describe the historical evolution and current state of the policies regulating office based prescribing of medications for opioid use disorder, and distinguish these from the federal regulations applicable to opioid treatment programs (OTPs). Participants will also be able to which identify which prescribing clinicians are eligible for the DATA-2000 waiver, the applicable waiver limits including the relevant practice settings impacting waiver limits, and the specific medications for opioid use disorder and clinic settings where the DATA-2000 does not apply. Participants will also be able to explain applicable privacy regulations and the regulations governing managing medications for opioid use disorder via telehealth. 

Educational Objectives:

  • Describe the legal differences between an opioid treatment program (OTP), hospital-managed MOUD, and office-based opioid treatment
  • Identify how X-waivered clinicians can increase their cap to increase the number of patients they can treat concurrently with buprenorphine products
  • Understand the rules regulating treating opioid use disorder with buprenorphine or methadone
  • Explain confidentiality rules governing substance use treatment records
  • Demonstrate how to appropriately manage MOUD using telemedicine
Summary
Availability: On-Demand
Expires on Jan 12, 2026
Cost: FREE
Credit Offered:
1 CME Credit
1 PA-CME Credit
1 Other Professionals Credit
1 Nursing Credit
1 Pharmacy Credit
1 IPCE Credit
Recommended
 
The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.



Funding for this initiative was made possible (in part) by grant nos. 1H79TI086770 and 1H79TI085588 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

 
PCSS-MOUD
PCSS-MOUD.org
pcss@aaap.org
For Buprenorphine Training Inquiries, email PCSS-MOUD.

ORN
opioidresponsenetwork.org

Powered By